Patents by Inventor Erwin Boghaert

Erwin Boghaert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMOR-INITIATING CELLS AND METHODS FOR USING SAME
    Publication number: 20160326496
    Abstract: Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof.
    Type: Application
    Filed: April 14, 2016
    Publication date: November 10, 2016
    Applicant: WYETH LLC
    Inventors: Marc Isaac Damelin, Kenneth G. Geles, Jonathon P. Golas, Erwin Boghaert, Bin-Bing S. Zhou
  • Tumor-initiating cells and methods for using same
    Patent number: 9340774
    Abstract: Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: May 17, 2016
    Assignee: Wyeth LLC
    Inventors: Marc Isaac Damelin, Kenneth G. Geles, Jonathon P. Golas, Erwin Boghaert, Bin-Bing S. Zhou
  • TUMOR-INITIATING CELLS AND METHODS FOR USING SAME
    Publication number: 20120071350
    Abstract: Isolated and enriched tumor-initiating cell populations, methods for preparing the same, and uses thereof.
    Type: Application
    Filed: March 26, 2010
    Publication date: March 22, 2012
    Applicant: WYETH LLC.
    Inventors: Marc Isaac Damelin, Kenneth G, Geles, Jonathon P. Golas, Erwin Boghaert, Bin-Bings S. Zhou
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20070231333
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: March 9, 2007
    Publication date: October 4, 2007
    Applicant: Wyeth
    Inventors: Erwin BOGHAERT, Nitin Damle, Philip Hamann, Kiran Khandke, Arthur Kunz, Kimberly Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar
  • Passive targeting of cytotoxic agents
    Publication number: 20070190060
    Abstract: The present invention provides methods of treating cancer cells comprising administering to a patient in need thereof a therapeutically effective amount of a non-specific antibody conjugated to a cytotoxin, wherein the cancer cells do not express an antigen to which the non-specific antibody binds. In one embodiment, the non-specific antibody is an anti-CD33 antibody (e.g., hp67.6), an anti-CD22 antibody (e.g., g5/44), or an anti-CD20 antibody (e.g., rituximab). In another embodiment, the non-specific antibody does not bind a human antigen. The cancer cells treated can be, e.g., gastric, colon, non-small cell lung (NSCLC), breast, epidermoid, or prostate carcinoma cells. In one embodiment, the cytotoxin is calicheamicin. Calicheamicin can be conjugated to the non-specific antibody using a 4-(4?-acetylphenoxy)butanoic acid (AcBut) or (3-Acetylphenyl)acetic acid (AcPAc) linker.
    Type: Application
    Filed: March 15, 2005
    Publication date: August 16, 2007
    Applicant: Wyeth
    Inventors: Erwin Boghaert, Kiran Khandke, Nitin Damle
  • METHODS OF DETERMINING PHARMACOKINETICS OF TARGETED THERAPIES
    Publication number: 20070003559
    Abstract: Methods for determining pharmacokinetics of targeted therapies.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 4, 2007
    Applicant: Wyeth
    Inventors: Kiran Khandke, Nitin Damle, Erwin Boghaert
  • Humanized anti-5T4 antibodies and anti-5T4/calicheamicin conjugates
    Publication number: 20060088522
    Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: September 9, 2005
    Publication date: April 27, 2006
    Applicant: Wyeth
    Inventors: Erwin Boghaert, Nitin Damle, Davinder Gill, Kimberly Marquette, Lioudmila Tchistiakova, Philip Hamann, Arthur Kunz